A Phase 2 interventional study of GI-102 in combination with GIB-7 and Placebo in Cancer Survivors, Healthy Participant and Elderly, sponsored by GI Innovation, Inc.. Recruiting at 2 sites in Australia. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-26.
Sponsored by GI Innovation, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This Phase 2a clinical study (GIANTS-1) aims to evaluate a novel dual-combination strategy using GI-102 and GIB-7 to address key pathological features of aging, including immunosenescence (the aging of the immune system), metabolic dysfunction, and gut-brain-muscle axis dysregulation.
GI-102 targets immunosenescence and inflammation: GI-102 is a bispecific immunocytokine composed of CD80 fused with a mutated interleukin (IL)-2. It is currently being evaluated in an ongoing Phase 2 oncology study, in which its safety and tolerability has been evaluated. Clinically meaningful biological activity-such as increased peripheral lymphocyte counts (including CD8+ T cells and natural killer [NK] cells)-has been observed, supporting its potential role in immune reactivation and inflammation modulation in the aging population.
GIB-7 restores gut-brain-muscle axis and circadian rhythm: GIB-7 is a proprietary synbiotic formulation that contains four probiotic strains- Limosilactobacillus fermentum, Lactiplantibacillus plantarum, which are gram-positive lactic acid bacteria. Additionally, it contains the strains Lactobacillus acidophilus, and Bifidobacterium animalis subsp. lactis. These components collectively support gut microbial stability and systemic physiological balance. In a clinical study conducted in healthy older adults (NCT05735418), GIB-7 demonstrated significant improvements in grip strength and reductions in inflammatory markers, with no investigational product (IP)-related adverse events (AEs), confirming its excellent safety profile. Additionally, GIB-7 has been shown to support circadian rhythm regulation, a key aspect of homeostatic aging that is often disrupted in older adults.
The rationale for combining these two agents is their complementary mechanisms:
This dual-combination strategy addresses complementary hallmarks of aging, offering a mechanistically integrated approach to extending healthspan (the period during which individuals remain functional and free of chronic diseases) in healthy adults and cancer survivors.
GI Innovation, Inc. is the lead sponsor of 5 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Participants with a history of cancer may be included only if they meet one of the following:
For those diagnosed within 2 years:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GI-102 in combination with GIB-7
Combination Product: GI-102 in combination with GIB-7
GI-102 in combination with GIB-7
Combination Product: GI-102 in combination with GIB-7
Placebo for GI-102 in combination with GIB-7
Combination Product: Placebo
Drug page: Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102
GI-102: recombinant protein drug, intravenous (IV) infusion, once every 4 weeks (Q4W); GIB-7: synbiotic formula, oral administration, once daily (QD)
Also known as: efzilonkofusp alfa in combination with GIB-7
Placebo for GI-102 in combination with GIB-7
Change in Baseline values in immune response (NK cells) before and after GI-102 and GIB-7 combination treatment
Maximum change from Baseline values in immune function, primarily in natural killer (NK) cells assessed by flow cytometry in blood samples.
Time frame: From Day 1 until Week 10 visit
Change in Baseline values in immune response (CD8+ T cells) before and after GI-102 and GIB-7 combination treatment
Maximum change from Baseline values in immune function, primarily in CD8⁺ T cells assessed by flow cytometry in blood samples.
Time frame: From Day 1 until Week 10 visit
Frequency of Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) of the combination of GI-102 and GIB-7 by severity
Frequency of Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) by severity.
Time frame: From Day 1 until Week 10 visit
Number of participants with various adverse events and abnormal lab data
Number of participants with Treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), abnormal Vital signs, abnormal Electrocardiograms (ECGs), abnormal Physical examination findings, abnormal Chest X-ray, or abnormal Laboratory tests results
Time frame: From Day 1 until Week 10 visit
Change in Baseline values in sleep quality before and after GI-102 and GIB-7 combination treatment
Change from Baseline values in sleep quality using ISI (Insomnia Severity Index) at Week 8 and Week 10
Time frame: From Day 1 until Week 10 visit
Change in Baseline values in quality of life before and after GI-102 and GIB-7 combination treatment
Change from Baseline values in quality of life using EQ-5D (EuroQol 5 Dimension) at Week 8 and Week 10
Time frame: From Day 1 until Week 10 visit
Change in Baseline values in muscle function (hand grip strength) before and after GI-102 and GIB-7 combination treatment
Change from Baseline values in muscle function using hand grip strength test at Week 8 and Week 10
Time frame: From enrollment to the end of study
Change in Baseline values in muscle function (6 minute walk test) before and after GI-102 and GIB-7 combination treatment
Change from Baseline values in muscle function using 6 minute walk test at Week 8 and Week 10
Time frame: From enrollment to the end of study
Change in Baseline values in the hospital visits by GI-102 and GIB-7 combination treatment
Number of hospital visits compared to placebo at Week 8 and Week 10 (falls, fractures, pneumonia or severe respiratory illness, and other major health events may also be collected) to be conducted in a subgroup analysis (≥ 50 years)
Time frame: From Day 1 until Week 10 visit
Change in Baseline values in gut microbiome by GI-102 and GIB-7 combination treatment
Change from Baseline values in gut microbiome at Week 8 and Week 10 as indicated by fecal microbiota changes using alpha-diversity values and taxonomic relative abundances.
Time frame: From Day 1 until Week 10 visit
Change in Baseline values in cognitive function by GI-102 and GIB-7 combination treatment
Change from Baseline values in cognitive function at Week 8 and Week 10 as assessed by MoCA (Montreal Cognitive Assessment)
Time frame: From Day 1 until Week 10 visit
Survival (cancer survivors only)
In this study investigators will monitor overall survival defined as time from the inclusion to death or end of follow up at Week 10 (whichever comes first).
Time frame: From Day 1 until Week 10 visit
Recurrence (cancer survivors only)
In this study investigators will monitor cancer recurrence defined as time from the inclusion to the first recurrence or end of follow up at Week 10 (whichever comes first).
Time frame: From Day 1 until Week 10 visit
Plan to share: Yes — Data and biospecimens collected in this study may be accessed by the XPRIZE Foundation and its designated Judging Panel solely for the purpose of verifying study results and evaluating eligibility for the XPRIZE Healthspan Competition. No identifiable personal information will be shared, and all data provided will remain confidential and used only for competition judging and audit purposes.
No publications or documents are linked to this record.
Start is estimated for Jan 2026; primary completion for May 2026, 4 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102
GI Innovation, Inc.